Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07362888 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Adcendo ApS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT07362888 is a Phase 1 study that is actively recruiting participants, run by Adcendo ApS. The registered enrollment target is 180 participants.
The verdict
NCT07362888, a Phase 1 study, is actively recruiting participants, sponsored by Adcendo ApS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
Interventions
- DRUG ADCE-B05
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-03-17 |
| Est. Completion | 2029-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07362888
The ClinicalTrials.gov registry entry for NCT07362888 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adcendo ApS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADCE-B05 is the first listed.
NCT07362888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07362888 about?
NCT07362888 is a clinical study titled "First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors". The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
What is the current status of trial NCT07362888?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-03-17. Estimated completion is 2029-03-14.
What interventions are being tested in trial NCT07362888?
The interventions under investigation include: ADCE-B05 (DRUG).
Who is sponsoring clinical trial NCT07362888?
This trial is sponsored by Adcendo ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.